Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Malignant Solid Neoplasm|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Locally Advanced Malignant Solid Neoplasm|Malignant Female Reproductive System Neoplasm|Metastatic HER2-Negative Breast Carcinoma|Metastatic Malignant Solid Neoplasm|Recurrent Endometrial Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Malignant Female Reproductive System Neoplasm|Recurrent Malignant Solid Neoplasm|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Unresectable HER2-Negative Breast Carcinoma|Unresectable Malignant Solid Neoplasm
Interventions: DRUG: Alpelisib|DRUG: Binimetinib|PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Marrow Aspiration|PROCEDURE: Bone Scan|PROCEDURE: Computed Tomography|PROCEDURE: Echocardiography|DRUG: Fluorouracil|DRUG: Fulvestrant|DRUG: Ipatasertib|DRUG: Leucovorin|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE: Multigated Acquisition Scan|PROCEDURE: Mutation Carrier Screening|DRUG: Neratinib Maleate|DRUG: Nilotinib Hydrochloride Monohydrate|DRUG: Olaparib|DRUG: Oxaliplatin|DRUG: Paclitaxel|DRUG: Palbociclib|BIOLOGICAL: Panitumumab|PROCEDURE: Positron Emission Tomography|DRUG: Selumetinib Sulfate|DRUG: Sotorasib
Sponsor: National Cancer Institute (NCI)